Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Cancer Res. 2020 Jul 24;26(21):5701–5708. doi: 10.1158/1078-0432.CCR-20-1825

Figure 4.

Figure 4.

PD-L1 expression, tumor mutational burden, and immune checkpoint inhibitor (ICI) outcomes. (A) Overall survival among patients with SMARCA4 alterations who did and did not receive ICIs. (B) Tumor mutational burden (TMB) by SMARCA4 alteration class. (C) PD-L1 expression frequency by SMARCA4 alteration class. (D) Overall response rate by SMARCA4 alteration class. (E) Progression-free survival by SMARCA4 alteration class. (F) Overall survival by SMARCA4 alteration class.